Text of the Food and Drug Administration Mission Reform Act of 2011

This bill was introduced on October 14, 2011, in a previous session of Congress, but was not enacted. The text of the bill below is as of Oct 14, 2011 (Introduced).

Download PDF

Source: GPO



1st Session

H. R. 3214


October 14, 2011

(for himself, Mrs. Myrick, Mrs. Blackburn, Mrs. McMorris Rodgers, Mr. Guthrie, Mr. Shimkus, Mrs. Bono Mack, Mr. Latta, and Mr. Paulsen) introduced the following bill; which was referred to the Committee on Energy and Commerce


To amend the Food and Drug Administration’s mission.


Short title

This Act may be cited as the Food and Drug Administration Mission Reform Act of 2011.


FDA’s mission

Section 1003(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393(b)) is amended—


in paragraph (2), by striking with respect to such products and inserting with respect to regulated products;


in paragraph (4), by striking (1) through (3) and inserting (1) through (4);


by redesignating paragraphs (2) through (4) as paragraphs (3) through (5); and


by inserting after paragraph (1) the following:


establish a regulatory system that—


advances medical innovation by incorporating modern scientific tools, standards, and approaches to ensure the predictable, consistent, efficient, and reasonable review, clearance, approval, and licensing (as appropriate) of innovative products, including drugs, devices, and biological products;


protects the public health and enables patients to access novel products while promoting economic growth, innovation, competitiveness, and job creation among the industries regulated by this Act;


is based on the best available science;


allows for public participation and an open exchange of ideas;


promotes predictability, allows flexibility, and reduces uncertainty;


identifies and uses the most innovative and least burdensome tools for achieving regulatory ends;


ensures that regulations are accessible, consistent, transparent, written in plain language, and easy to understand;


measures, and seeks to improve, the actual results of regulatory requirements; and


incorporates a patient-focused benefit-risk framework that accounts for varying degrees of risk tolerance, including for people living with a life-impacting chronic disease or disability;